Ertiprotafib

DB06521ExperimentalSmall molecule

Ertiprotafib belongs to a novel class of insulin sensitizers developed for treatment of type 2 diabetes. In insulin-resistant rodent models, ertiprotafib and a close analog lowered both fasting blood glucose...

Mechanism: The complete mechanism of action for ertiprotafib and related compounds in vivo may involve multiple independent mechanisms, including (but not necessarily limited to) PTP1b inhibition and dual PPARalpha/PPARgamma agonism.
Curator reviewed
Primary indication: Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
Formula / weight: C₃₁H₂₇BrO₃S · 559.52 g/mol (avg)
Code names: PTP-112

Resolves to

Compound

UNII5TPM2EB426CAS251303-04-5ChEMBLCHEMBL184041

Structure

InChIKeyFONCZICQWCUXEB-RUZDIDTESA-NSMILESCC1=C(C)C2=C(C3=CC(C)=C(O[C@H](CC4=CC=CC=C4)C(O)=O)C(C)=C3)C3=CC=CC=C3C(Br)=C2S1

Targets

P18031PTPN1O14920IKBKBQ07869PPARAP37231PPARG

What you can answer from here — as of March 06, 2025

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Ertiprotafib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account